What the NICE Guidance on Mounjaro Means for You

You've seen Mounjaro discussed online, here's what NICE actually decided

Imagine you've spent weeks reading about tirzepatide: the trial results, the social media chatter, maybe a conversation with your GP that ended with a shrug and a six-month wait. Then you search for the official position and land on a wall of clinical language. The short version is this: NICE's appraisal of tirzepatide concluded that the medicine is clinically and cost-effective for adults with a BMI of 35 or above who also have at least one weight-related comorbidity, conditions such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

The appraisal committee reviewed data from the SURMOUNT programme, which enrolled thousands of adults across multiple trials. At the 15mg maintenance dose, participants lost an average of around 20–21% of their body weight over 72 weeks, figures that gave NICE enough confidence to recommend it, as detailed in the full NICE guidelines on Mounjaro. That recommendation came with a condition: if someone hasn't lost at least 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reconsidered. The guidance is not a blank cheque; it is a structured clinical framework.

One thing the guidance does not do is open the NHS taps overnight. NICE recommends; NHS England then decides how and when to commission. For tirzepatide, that has meant a phased rollout tied to BMI and the number of qualifying conditions a person has.

The NHS phased rollout: which cohort is open right now

NHS England has structured access to Mounjaro in stages, and understanding where the current boundary sits matters if you are trying to work out whether you qualify today. From June 2025, the first cohort opened: adults with a BMI of 40 or above who also have four or more of the five qualifying conditions listed above. Cohort 2 (covering adults with a BMI between 35 and 39.9 plus four or more of those conditions) became available from 23 June 2026. Further cohorts, including those with fewer qualifying conditions, are expected from around March 2027 onwards.

The ethnic-background adjustment matters here too. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, each BMI threshold in the guidance is reduced by 2.5 kg/m². So a threshold of 40 effectively becomes 37.5, and 35 becomes 32.5, for those groups. This is stated directly in NICE TA1026 and carried through into NHS commissioning. You can verify the full detail in NICE's published appraisal of tirzepatide (TA1026).

Even meeting the criteria on paper does not guarantee access. Every NHS patient must take part in structured diet and activity support alongside the medicine. GP practices may prescribe under the 2026/27 contract, but participation is optional, so provision varies by area. A question our prescribers hear most weeks is whether a patient's GP can prescribe Mounjaro on the NHS yet. The honest answer is: sometimes yes, often not yet, depending on where they live and which cohort is currently open. For people who fall outside the current NHS cohorts, or who simply cannot wait, a private route through a regulated pharmacy is an alternative, subject to the licensed eligibility criteria assessed by a real prescriber.

Private eligibility: the licensed criteria versus the NICE criteria

There is an important distinction between the NICE guidance and the medicine's UK licence. NICE TA1026 sets conditions for NHS reimbursement. The licence, granted by the MHRA based on the manufacturer's clinical data, sets out who the medicine is authorised to treat. For Mounjaro, that licensed population is broader: adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity. The Black Triangle (▼) status signals that the MHRA is collecting additional post-marketing data, standard for newer medicines.

Private prescribers, including those at regulated online pharmacies, work to the licensed criteria rather than the NICE commissioning thresholds. That means someone with a BMI of 32 and hypertension who does not meet the NHS cohort criteria may well be eligible for a private prescription, though a prescriber still assesses every individual case. BMI alone never determines the outcome; the full clinical picture matters. You can read more about the medicine itself on our Mounjaro overview page, and explore all available weight-loss treatments at our weight-loss treatments page.

The NICE Mounjaro guidance also specifies that treatment should be stopped if the 5% weight-loss benchmark is not met at six months. Private prescribers apply equivalent clinical review at dose increases and before each repeat, the principle of ongoing clinical oversight is the same whichever route you use. You can find detail on the prescriber-led review process in our practical guide to Mounjaro.

What NICE TA1026 does not cover, and what happens next

NICE guidance is not static. TA1026 was published in December 2024 and updated in September 2025; future reviews may widen or adjust the commissioning criteria as longer-term evidence accumulates. The guidance also covers only England, Scotland, Wales and Northern Ireland have separate processes, with differing thresholds and timelines. If you are based in Scotland, the NHS Inform page on weight-loss medication is a useful starting point alongside the NICE appraisal.

The guidance does not provide dosing instructions for individual patients; that is the prescriber's role, informed by the medicine's Summary of Product Characteristics. It does not address every clinical scenario, people with a history of medullary thyroid carcinoma or MEN2, for example, require specific prescriber discussion, as do those who are pregnant, breastfeeding or planning a pregnancy. Mounjaro is not licensed for under-18s. These boundaries exist regardless of whether access is NHS or private.

If you want to understand whether you meet the criteria and what a clinical consultation would involve, our tirzepatide information page covers the clinical picture in more depth. Alternatively, the BNF entry for tirzepatide is the professional reference prescribers use. When you are ready to take the next step, starting a free consultation connects you with a GPhC-registered prescriber who reviews your case the same day.